Back

Extended, standard or de-escalation antiplatelet therapy after ACS?

18 March 2022 (13:04 - 13:17)
Organised by:
Congress Presentation Part of: Anti-thrombotic management in patients with acute coronary syndromes (ACS) Thrombosis, Platelets, and Coagulation ACVC Premium Access ESC Acute CardioVascular Care 2022

About the speaker

Photo
Professor Kurt Huber

Sigmund Freud University Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail
The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction
Mr S. Rikken (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Antiplatelet pretreatment in NSTE-ACS: do we have the answer?
Doctor P. Capranzano (Catania, IT)
Slides Video
Presentation thumbnail
Do we really need aspirin?
Professor R. Mehran (New York City, US)
Slides Video
Presentation thumbnail
Anti-thrombotic management in patients with acute coronary syndromes - discussion.
Video

Access the full session

Session thumbnail
Anti-thrombotic management in patients with acute coronary syndromes (ACS)
Video

The Event

Event poster

ESC Acute CardioVascular Care 2022

18 March 2022 13:04 CET